ArticleTranslational cancer research2026
A novel prognostic model based on vasculogenic mimicry in ovarian cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-grade serious ovarian cancer (HGSOC) is a heterogeneous gynecological malignancy with high mortality, often diagnosed at advanced stages, and its prognosis remains poor despite therapeutic advances. Discovering innovative prognostic markers and developing predictive models are critical to improving treatment strategies in patients with HGSOC. Vasculogenic mimicry (VM), a tumor cell-derived vessel-like structure formation process, plays a critical role in tumor progression and is linked to poor prognosis, making it a potential target for prognostic biomarker development. In this study, we aimed to construct a VM-related prognostic risk model for HGSOC. Methods: We analyzed transcriptomic and clinical data of HGSOC patients from the GSE9891 and The Cancer Genome Atlas (TCGA) database, identified VM-related genes, and developed a prognostic model using least absolute shrinkage and selection operator (LASSO)-Cox regression. The model's performance was validated via survival analysis, receiver operating characteristic (ROC) curves, and independent prognostic factor assessment in both training and test sets. Additionally, a nomogram integrating the model with clinical variables was established to optimize prognostic prediction. At the same time, we performed gene ontology (GO) analysis of differential genes in high- and low-risk HGSOC patients to obtain common enrichment pathways. Finally, after the survival analysis, we selected Results: In this study, we systematically developed an HGSOC prognostic risk model founded on seven VM genes. Furthermore, we formulated a new nomogram that combines risk characteristics and clinical pathological features, which provided good predictive performance for the clinical prognosis of HGSOC patients. At the same time, we found that Conclusions: We identified VM-related genes, constructed a prognostic risk model for HGSOC, and found that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.